The intravenous drug represents a new treatment for relapsing forms of MS and the first treatment for primary progressive MS — the most disabling form of the disease.
About 15 percent of MS patients are diagnosed with PPMS, which occurs when a patient’s symptoms steadily worsen with any relapses or remissions, according to the CDC.
Genentech expects Ocrevus to be available in the U.S. by mid-April, according to a company news release.
More articles on supply chain:
7 must-reads for supply chain leaders this week
America’s focus on technology — rather than medicine — is ‘eroding our national intellect,’ says pharma exec
Bill Ackman calls $4B Valeant investment ‘huge mistake’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
